Journals / ANKEM Dergisi / 2008 / Cilt: 22 - Sayı: 1

Efficiency of fosfomycin trometamol on Escherichia coli strains from community acquired urinary tract ınfections

Toplum kökenli üriner sistem infeksiyonu etkeni Escherichia coli suşlarında fosfomisin trometamol etkinliği

Pages
23–27
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In conclusion, fosfomycin trometamol seems to be a good alternative that should be considered for the treatment of community acquired lower urinary tract infections.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Escherichia coli is the most commonly isolated microorganism in uncomplicated lower urinary tract infections (UTI).
📊
Key Findings & Data:Due to the increased antibiotic-resistance rates in E.coli strains, it is important to have alternative drugs for the therapy of UTIs caused by this pathogen.
💡
Conclusion & Impact:In conclusion, fosfomycin trometamol seems to be a good alternative that should be considered for the treatment of community acquired lower urinary tract infections.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Escherichia coli · Fosfomisin · Mikrobiyal duyarlılık testleri

Abstract

Escherichia coli is the most commonly isolated microorganism in uncomplicated lower urinary tract infections (UTI). Due to the increased antibiotic-resistance rates in E.coli strains, it is important to have alternative drugs for the therapy of UTIs caused by this pathogen. In this study, we tested the in vitro susceptibility of 169 clinical urinary isolates of E.coli isolated from community acquired women cases to fosfomycin trometamol in comparison with amoxicillin-clavulanate, cefotaxime, cefazolin, ciprofloxacin, gentamicin, imipenem, and trimethoprim-sulphametoxazole. The identification was performed by conventional methods. Antimicrobial susceptibility tests were performed by Kirby Bauer disk diffusion method according to the CLSI criteria. Only one strain (0.6 %) was found resistant to fosfomycin tromethamol, while no resistance was determined against imipenem. The percentages of resistant strains were found to be 58 % for trimethoprim-sulphametoxazole, 35.5 % for cefazolin, and 34.9 % for ciprofloxacin. In conclusion, fosfomycin trometamol seems to be a good alternative that should be considered for the treatment of community acquired lower urinary tract infections.

Özet

Escherichia coli komplike olmayan alt üriner sistem infeksiyonlarından (ÜSİ) en sık izole edilen etkendir. E.coli suşlarında antibiyotik direnç oranlarının artışı, bu patojenin etken olduğu ÜSİ’nun tedavisinde kullanılabilecek alternatif ilaç arayışını daha önemli hale getirmiştir. Bu çalışmada, kadın hastalardan toplum kökenli 169 üriner E.coli izolatının fosfomisin trometamol yanısıra, amoksisilin-klavulanik asit, trimetoprim-sülfametoksazol, siprofloksasin, gentamisin, sefazolin, seftriakson ve imipenem gibi antimikrobiyallere karşı in-vitro duyarlılığı araştırılmıştır. Bakteri tanımlanması konvansiyonel metodlarla yapılırken antimikrobiyal duyarlılık testleri Kirby Bauer disk difüzyon metoduyla ve CLSI kriterleri doğrultusunda belirlenmiştir. İmipeneme direnç saptanmazken sadece bir suş (% 0.6) fosfomisin trometamole dirençli bulunmuştur. Diğer antibiyotiklere direnç oranları trimetoprim-sülfametoksazol için % 58, sefazolin için % 35.5, siprofloksasin için % 34.9 olarak bulunmuştur. Bulgularımızın da gösterdiği gibi fosfomisin trometamol komplike olmayan alt ÜSİ’nin tedavisinde kullanılabilecek güvenilir, etkili ve ucuz bir antibiyotiktir.

🔖

Cite This Article

KÖKEN, G., AŞIK, G., ÇİFTÇİ, İ. H., ÇETİNKAYA, Z., AKTEPE, O. C., YILMAZER, M. (2008). Efficiency of fosfomycin trometamol on Escherichia coli strains from community acquired urinary tract ınfections. ANKEM Dergisi, Cilt: 22 - Sayı: 1, 23–27. https://ajindex.com/articles/190297

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Afşar İ, Gönül B, Şener AG, Türker M: Escherichia coli’nin klinik izolatlarının fosfomisin trometamol ve diğer antibiyotiklere in-vitro duyarlılığı, ANKEM Derg 2005;19(2):77-9
  2. Arca AE, Karabiber N: Üriner sistem E.coli izolatları nın fosfomisin trometamol ve çeşitli antibiyotiklere karşı duyarlılıklarının karşılaştırılması, Mikrobiyol Bült 2007;41(1):115-9
  3. Arslan H, Azap OK, Ergonul O, Timurkaynak F, Urinary Tract Infection Study Group: Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey, J Antimicrob Chemother 2005;56(5):914-8
  4. Clinical and Laboratory Standards Institute: Performance Standards for Antimicrobial Susceptibility Testing: Fifteenth Informational Supplement M100-S15, CLSI, Wayne, Pa (2005)
  5. Deveci Ö, Tayfun SS, Kaygusuz S, Kılıç D, Ağalar C: Üriner sistem infeksiyonu etkeni E.coli flusları nda fosfomisin duyarlılığınınn araştırılması, KLiMiK 2005, XII.Türk Klinik Mikrobiyoloji ve infeksiyon Hastalıkları Kongresi, Kongre kitabı s.266 (PO5-17), Antalya, 16-20 Kasım (2005)
  6. Foxman B: Epidemiology of urinary tract infections: Incidence, morbidity, and economic costs, Am J Med 2002;113(Suppl 1A):5-13
  7. Gobernado M, Valdés L, Alós JI, García-Rey C, Dal-Ré R, García-de-Lomas J, Spanish Surveillance Group for Urinary Pathogens: Antimicrobial susceptibility of clinical Escherichia coli isolates from uncomplicated cystitis in women over a 1- year period in Spain, Rev Esp Quimioterap 2007;20(1):68-76
  8. Hooton TM: Practice guidelines for urinary tract infection in the era of managed care, Int J Antimicrob Agents 1999;11(3-4):241-5
  9. Hooton TM, Stamm WE: Diagnosis and treatment of uncomplicated urinary tract infection, Infect Dis Clin North Am 1997;11(3):551-81
  10. Krcmery S, Hromec J, Demesova D: Treatment of lower urinary tract infection in pregnancy, Int J Antimicrob Agents 2001;17(4):279-82
  11. Marchese A, Gualco L, Debbia EA, Schito AM: Invitro activity of fosfomycin against gram-negative urinary pathogens and the biological cost of fos fomycin resistance, Int J Antimicrob Agents 2003;22(Suppl 2):53-9
  12. Naber KG: Treatment options for acute uncomplicated cystitis in adults, J Antimicrob Chemother 2000;46(Suppl 1):23-7
  13. Neu HC: Fosfomycin trometamol versus amoxycillin- single-dose multicenter study of urinary tract infections, Chemotherapy 1990;36(Suppl 1):19-23
  14. Nicolle LE: Empirical treatment of acute cystitis in women, Int